Showing results (271-280 of 401) with videos related to

Sort By:
Pageof 41
Journal of the National Cancer Institute|October 11, 2023
Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminomaDaniel D Joyce, Vidit Sharma, Kevin M Wymer, et al.
International Urology and Nephrology|June 5, 2021
Perioperative outcomes of goal-directed versus conventional fluid therapy in radical cystectomy with enhanced recovery protocolAlireza Ghoreifi, Michael F Basin, Saum Ghodoussipour, et al.
The Journal of Urology|April 15, 2024
Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical TrialHooman Djaladat, Alireza Ghoreifi, Tapas Tejura, et al.
European Urology|June 9, 2012
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancerJoshua J Meeks, Joaquim Bellmunt, Bernard H Bochner, et al.
Frontiers in Endocrinology|February 21, 2013
Cryptorchidism and testicular germ cell tumors: comprehensive meta-analysis reveals that association between these conditions diminished over time and is modified by clinical characteristicsKimberly Banks, Ellenie Tuazon, Kiros Berhane, et al.
BJU International|October 18, 2013
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapyPascal Zehnder, Urs E Studer, Siamak Daneshmand, et al.
World Journal of Urology|July 11, 2020
Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patient's undergoing urologic oncology surgery: a systematic reviewNathan A Brooks, Andrea Kokorovic, John S McGrath, et al.
Urologic Oncology|May 27, 2018
Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohortGiancarlo Marra, Paolo Gontero, Michele Brattoli, et al.
Urologic Oncology|January 13, 2026
Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case seriesAnosh Dadabhoy, Chirag Doshi, Mazyar Zahir, et al.
Urologic Oncology|April 18, 2022
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trialSiamak Daneshmand, Iris S G Brummelhuis, Kamal S Pohar, et al.
Pageof 41